Ep 26 - Martin Shkreli: The Case for Hims & Hers

This episode explores the intricacies of the healthcare industry, focusing on Hims & Hers' potential as a disruptive force and its valuation, featuring Martin Shkreli's insights. The discussion begins with Shkreli explaining his interest in Hims, driven by viewer requests and the company's unique position with both retail and institutional investors, praising CEO Andrew Dudum's vision and execution. Against the backdrop of Hims being compared to the "Netflix of healthcare," Shkreli emphasizes the company's impressive revenue growth and its potential to expand further within the multi-trillion dollar healthcare market. As the discussion pivoted to GLP-1s, Shkreli provides a historical overview and debates their long-term impact, while also touching on intellectual property rights and the role of compounding pharmacies. More significantly, the conversation shifts to the dynamics of institutional investment, short selling, and market perceptions of Hims, with Shkreli arguing against the short thesis and highlighting the presence of sophisticated investors like Farallon and quant funds. Concluding with valuation, Shkreli suggests Hims could reach a $20 billion market cap in the near term, driven by scaling efficiencies and potential acquisitions, reflecting emerging industry patterns where technology and innovative business models are poised to transform healthcare delivery.